Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Relationship of pharmacokinetically-calculated volumes of distribution to the physiologic distribution of liposomal drugs in tissues: implications for the characterization of liposomal formulations.

× No keyword cloud information.

16 in total

1. Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors.

Authors: E A Forssen; D M Coulter; R T Proffitt
Journal: Cancer Res Date: 1992-06-15 Impact factor: 12.701

2. A pharmacokinetic study of amphotericin B lipid complex injection (Abelcet) in patients with definite or probable systemic fungal infections.

Authors: A Adedoyin; C E Swenson; L E Bolcsak; A Hellmann; D Radowska; G Horwith; A S Janoff; R A Branch
Journal: Antimicrob Agents Chemother Date: 2000-10 Impact factor: 5.191

Review 3. Novel applications of liposomes.

Authors: D D Lasic
Journal: Trends Biotechnol Date: 1998-07 Impact factor: 19.536

4. Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats.

Authors: G W Boswell; I Bekersky; D Buell; R Hiles; T J Walsh
Journal: Antimicrob Agents Chemother Date: 1998-02 Impact factor: 5.191

5. Safety and toxicokinetics of intravenous liposomal amphotericin B (AmBisome) in beagle dogs.

Authors: I Bekersky; G W Boswell; R Hiles; R M Fielding; D Buell; T J Walsh
Journal: Pharm Res Date: 1999-11 Impact factor: 4.200

Review 6. Physiological parameters in laboratory animals and humans.

Authors: B Davies; T Morris
Journal: Pharm Res Date: 1993-07 Impact factor: 4.200

7. Pharmacokinetics and urinary excretion of amikacin in low-clearance unilamellar liposomes after a single or repeated intravenous administration in the rhesus monkey.

Authors: R M Fielding; L Moon-McDermott; R O Lewis; M J Horner
Journal: Antimicrob Agents Chemother Date: 1999-03 Impact factor: 5.191

8. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients.

Authors: O Ringdén; F Meunier; J Tollemar; P Ricci; S Tura; E Kuse; M A Viviani; N C Gorin; J Klastersky; P Fenaux
Journal: J Antimicrob Chemother Date: 1991-10 Impact factor: 5.790

9. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice.

Authors: M S Newman; G T Colbern; P K Working; C Engbers; M A Amantea
Journal: Cancer Chemother Pharmacol Date: 1999 Impact factor: 3.333

10. Pharmacokinetics, toxicity, and efficacy of liposomal capreomycin in disseminated Mycobacterium avium beige mouse model.

Authors: P Le Conte; F Le Gallou; G Potel; L Struillou; D Baron; H B Drugeon
Journal: Antimicrob Agents Chemother Date: 1994-12 Impact factor: 5.191

2 in total

1. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans.

Authors: Ihor Bekersky; Robert M Fielding; Dawna E Dressler; Jean W Lee; Donald N Buell; Thomas J Walsh
Journal: Antimicrob Agents Chemother Date: 2002-03 Impact factor: 5.191

2. Pharmacokinetics and buccal mucosal concentrations of a 15 milligram per kilogram of body weight total dose of liposomal amphotericin B administered as a single dose (15 mg/kg), weekly dose (7.5 mg/kg), or daily dose (1 mg/kg) in peripheral stem cell transplant patients.

Authors: Paul O Gubbins; Jarrett R Amsden; Scott A McConnell; Elias J Anaissie
Journal: Antimicrob Agents Chemother Date: 2009-06-22 Impact factor: 5.191

2 in total